Varilrix

ApprovedBiologic

GSK

Varilrix is one of 73 biologic programs targeting Chickenpox. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChickenpoxActive, not recruiting

ImmunodeficiencyActive, not recruiting

InfluenzaActive, not recruiting

ChickenpoxPhase 3

Active, not recruiting

ImmunodeficiencyApproved

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Varilrix

GSK

Approved

1 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Crestor

AstraZeneca

Preclinical

1 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Varicella3 trials

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Completed· GSK logo

GSK·Phase 3·NCT00969436·450 enrolled

A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.

Completed· GSK logo

GSK·Phase 3·NCT02570126·1,236 enrolled

Study of Two Formulations of GSK Biologicals' Varicella Vaccine

Completed· GSK logo

GSK·Phase 2·NCT00568334·244 enrolled

Children1 trial

Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00624819·524 enrolled

Chickenpox1 trial

Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox

Completed· GSK logo

GSK·Phase 3·NCT00226499·5,803 enrolled

Influenza1 trial

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Completed· GSK logo

GSK·Phase 3·NCT01439360·12,046 enrolled

Immunodeficiency1 trial

Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox

Unknown status·HHelsinki University Central Hospital·Phase 4·NCT02383797·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Varilrix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Varilrix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Varilrix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: GSK

Varilrix

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Varicella3 trials

Children1 trial

Chickenpox1 trial

Influenza1 trial

Immunodeficiency1 trial

References

Drug Info

Quick Facts

Related News